Buprenorphine Dispensing after Elimination of the Waiver Requirement.
作者信息
Chua Kao-Ping, Bicket Mark C, Bohnert Amy S B, Conti Rena M, Lagisetty Pooja, Nguyen Thuy D
机构信息
University of Michigan Medical School, Ann Arbor, MI
Boston University Questrom School of Business, Boston, MA.
出版信息
N Engl J Med. 2024 Apr 25;390(16):1530-1532. doi: 10.1056/NEJMc2312906.
Abstract
摘要
相似文献
1
Buprenorphine Dispensing after Elimination of the Waiver Requirement.
N Engl J Med. 2024 Apr 25;390(16):1530-1532. doi: 10.1056/NEJMc2312906.
2
Buprenorphine dispensing before and after the April 2021 X-Waiver exemptions: An interrupted time series analysis.
Int J Drug Policy. 2024 Apr;126:104381. doi: 10.1016/j.drugpo.2024.104381. Epub 2024 Mar 8.
3
National- and State-Level Pharmacy-Based Buprenorphine Dispensing, United States 2019-2021.
J Gen Intern Med. 2024 Aug;39(10):1951-1953. doi: 10.1007/s11606-024-08829-0. Epub 2024 May 28.
4
Why 24 State and Territorial Health Officials Support Buprenorphine Deregulation.
Am J Public Health. 2019 Dec;109(12):1678-1679. doi: 10.2105/AJPH.2019.305370.
5
Trends in Buprenorphine Treatment in the United States, 2009-2018.
JAMA. 2020 Jan 21;323(3):276-277. doi: 10.1001/jama.2019.18913.
6
Using buprenorphine to treat patients with opioid use disorder.
JAAPA. 2019 Oct;32(10):30-35. doi: 10.1097/01.JAA.0000580544.64346.d7.
7
Authors' Response on "Rise in Neonatal Abstinence Syndrome Rate Is Associated with Rise in Buprenorphine Prescription Numbers".
South Med J. 2024 Aug;117(8):511-512. doi: 10.14423/SMJ.0000000000001712.
8
Datapoints: regional variation in benzodiazepine prescribing for patients on opioid agonist therapy.
Psychiatr Serv. 2014 Jan 1;65(1):4. doi: 10.1176/appi.ps.650308.
9
Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US.
JAMA. 2021 Jun 1;325(21):2206-2208. doi: 10.1001/jama.2021.4469.
10
US ED Opioid-Related Visits Increase, While Use of Medication for Opioid Use Disorder Undetectable, 2011-2016.
J Gen Intern Med. 2020 Mar;35(3):965-966. doi: 10.1007/s11606-019-05249-3.
引用本文的文献
1
Factors associated with emergency room visits among patients with opioid use disorder: A study of buprenorphine-treated and untreated patients.
Drug Alcohol Depend Rep. 2025 Jun 6;16:100349. doi: 10.1016/j.dadr.2025.100349. eCollection 2025 Sep.
2
Prescriber-Level Changes in Buprenorphine Dispensing in the USA Before and After Federal Policy Changes Aimed at Increasing Prescribing.
J Gen Intern Med. 2025 Jun 25. doi: 10.1007/s11606-025-09655-8.
3
Concurrent Treatment of Opioid and Tobacco Use Disorder in a Telemedicine Clinic: Case Report of Breaking Through Barriers.
JMIR Form Res. 2025 May 15;9:e72872. doi: 10.2196/72872.
4
Medicaid Unwinding and Changes in Buprenorphine Dispensing.
JAMA Netw Open. 2025 May 1;8(5):e258469. doi: 10.1001/jamanetworkopen.2025.8469.
5
Trends in Access to Medications for Opioid Use Disorder.
JAMA Health Forum. 2025 Apr 4;6(4):e250393. doi: 10.1001/jamahealthforum.2025.0393.
6
Individuals Dispensed Buprenorphine in the United States Before and After Federal Policy Changes Aimed at Increasing Access.
J Addict Med. 2025 Feb 19. doi: 10.1097/ADM.0000000000001457.
7
Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study.
Drug Alcohol Depend. 2025 Mar 1;268:112586. doi: 10.1016/j.drugalcdep.2025.112586. Epub 2025 Jan 29.
8
Building a Better Base for Keeping Buprenorphine on Board for Surgery.
Anesthesiology. 2025 Feb 1;142(2):266-267. doi: 10.1097/ALN.0000000000005282. Epub 2025 Jan 14.
9
State drug caps associated with fewer Medicaid-covered prescriptions for opioid use disorder, 2017-2022.
Health Aff Sch. 2024 Dec 6;2(12):qxae165. doi: 10.1093/haschl/qxae165. eCollection 2024 Dec.
10
Racial and Ethnic Disparities in Referral Rejection From Postacute Care Facilities Among People With Opioid Use Disorder in Massachusetts.
J Addict Med. 2025;19(2):165-171. doi: 10.1097/ADM.0000000000001390. Epub 2024 Nov 8.
本文引用的文献
1
Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022.
JAMA. 2023 Apr 25;329(16):1402-1404. doi: 10.1001/jama.2023.1207.
2
Segmented regression analysis of interrupted time series studies in medication use research.
J Clin Pharm Ther. 2002 Aug;27(4):299-309. doi: 10.1046/j.1365-2710.2002.00430.x.
Zotero 插件